Related Experiment Video
Updated: May 18, 2026
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
The laboratory and the new oral anticoagulants
1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy. armando.tripodi@unimi.it
Background:
The new oral anticoagulants (NOAs) dabigatran, rivaroxaban, and apixaban have proved effective and safe when used in clinical trials, without a need to adjust the dose in response to laboratory testing. This demonstrated efficacy does not necessarily mean that the laboratory, considered the mainstay for the management of the old anticoagulants, will no longer play a role in treatment with NOAs.
Content:
Laboratories are involved in the management of anticoagulants in 2 ways. The first, monitoring, implies laboratory testing to assess the drug's effect and to adjust the dosage to maintain anticoagulation within the therapeutic interval. This consideration applies to the old drugs. The second way, measurement, implies laboratory evaluations of drug effect to determine whether patients are under- or over-anticoagulated, information that can be useful for decision-making in special circumstances. The latter applies to NOAs.
Summary:
Measurements of the effect of NOAs are indicated in several situations: (a) patients with adverse events (i.e., thrombotic/hemorrhagic), particularly those who present with overdosage owing to excessive drug intake or decreased clearance; (b) patients undergoing surgical procedures for ensuring that no residual drug remains in the circulation; (c) patients requiring anticoagulation reversal because of life-threatening hemorrhage; (d) patients with renal insufficiency, who are likely to accumulate the drug in the circulation; (e) patients with liver failure, because NOAs are metabolized by the liver; (f) patients taking other drugs that might increase/decrease the effects of NOAs via drug-drug interactions. The choice of tests is based on such characteristics as availability, linearity of the dose-response curve, standardization, and responsiveness to increasing drug dosage. Practitioners need to be aware that NOAs can interfere with the measurement of common hemostasis parameters.
Insights
Laboratory testing remains crucial for new oral anticoagulants (NOAs) in specific situations. While routine monitoring isn't needed, measurements are vital for adverse events, surgery, and special patient populations.
Area of Science:
- Pharmacology
- Clinical Chemistry
- Hematology
Background:
- New oral anticoagulants (NOAs) like dabigatran, rivaroxaban, and apixaban show efficacy and safety without routine laboratory monitoring.
- Historically, laboratories have been central to managing old anticoagulants through dose adjustment.
- Laboratories play a role in NOA management through drug effect measurement in specific clinical scenarios.
Purpose of the Study:
- To define the role of laboratory testing in the management of new oral anticoagulants.
- To identify specific clinical situations where laboratory measurement of NOA effects is indicated.
- To guide practitioners on the appropriate use and interpretation of laboratory tests for NOAs.
Main Methods:
- Review of existing literature and clinical trial data on NOAs.
- Analysis of laboratory testing principles and their application to NOAs.
- Identification of clinical circumstances necessitating NOA drug level assessment.
Main Results:
- Routine laboratory monitoring for NOA dose adjustment is not required.
- Laboratory measurements are indicated for patients experiencing adverse events (thrombotic/hemorrhagic), especially with suspected overdosage or altered clearance.
- Testing is also crucial for patients undergoing surgery, requiring anticoagulation reversal, or those with renal insufficiency, liver failure, or potential drug-drug interactions.
Conclusions:
- Laboratory testing for NOAs is essential for specific clinical situations, not routine monitoring.
- Test selection should consider availability, standardization, and responsiveness.
- Practitioners must be aware of potential interference of NOAs with standard hemostasis parameters.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Oral Drug Delivery Systems: Introduction
01:11Oral Drug Delivery Systems: Delayed-Release Systems